Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.R5 Pharmaceuticals, a company that develops and manufactures new medicines and clinical trial materials, is set to double the size of its site and create new facilities, to introduce new services to its current provision, in 2011. double in size by the end of 2011.
Subscribe to our email newsletter
Under the plan, R5 Pharma, a subsidiary of Aesica Pharmaceuticals, plans to build a new analytical chemistry laboratory this spring with the second stage of construction completing in the second half of 2011.
The R5 expansion follows Aesica’s recent announcement in December 2010 that it had acquired three manufacturing sites in Europe, almost doubling its workforce.
R5 Pharma managing director Paul Titley said they are set to double the size of the site and create new facilities, which will enable them to introduce new services to their current provision, is testament to the dedication.
Aesica supplies contract development and contract manufacturing services for formulated products and active pharmaceutical ingredients to pharma firms and emerging biotechnology organisations across the world.